Analytical Data
-
Gene name
CCL3L3
- Application
-
Alternative Names
464.2; C-C motif chemokine 3-like 1; CCL3L3; CL3L1_HUMAN; D17S1718; G0/G1 switch regulatory Protein 19-2; G0S19-2; LD78; LD78-beta(1-70); LD78-beta(5-70); LD78BETA; PAT 464.2; SCYA3L; SCYA3L1; Small-inducible cytokine A3-like 1; Tonsillar lymphocyte LD78 beta Protein
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P16619
-
Expression Region
24-93aa
-
AA Sequence
APLAADTPTA CCFSYTSRQI PQNFIADYFE TSSQCSKPSV IFLTKRGRQV CADPSEEWVQ KYVSDLELSA
-
Molecular Weight
7.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL3L3, also known as macrophage inflammatory protein-1 gamma, is a chemokine that plays a crucial role in the immune response and has been implicated in various inflammatory diseases and conditions, including cancer and autoimmune disorders. This protein is part of a larger family of CC chemokines, which are involved in the recruitment of immune cells to sites of inflammation. Research into CCL3L3 has been motivated by its potential as a therapeutic target and biomarker for disease progression, given its ability to modulate the immune environment. Studies have shown that CCL3L3 can influence the behavior of various immune cells, such as T cells and macrophages, thus contributing to the pathophysiology of inflammatory responses. The recombinant production of CCL3L3 facilitates detailed studies into its structure-function relationships and interactions with cell surface receptors, paving the way for the development of targeted therapies. Furthermore, understanding the biological activities of CCL3L3 can provide insights into its role in both innate and adaptive immunity, enhancing our comprehension of immune regulation and inflammation. As research advances, CCL3L3 may emerge as a pivotal player in novel therapeutic approaches for inflammatory diseases, emphasizing the need for continued exploration of its biological functions and therapeutic implications.
